Table 3. miR-320e expression levels and clinico-pathologic characteristics of stage II and III CRC patients in the validation cohort.

Characteristics stages II–III	Patient number	MiR-320e expression median (range)	P-value
Age (years)	67 (32–82)a
Genderb
Male	96 (57.5%)	0.00305 (0–0.022)	0.9638
Female	71 (42.5%)	0.00300 (0.00033, 0.028)
Tumour locationb
Distal	113 (67.7%)	0.00310 (0.00023–0.022)	0.3618
Proximal	54 (32.3%)	0.00225 (0–0.028)
Tumour sizeb
<45 mm	72 (46.8%)	0.0025 (0.00013–0.028)	0.1047
>45 mm	82 (53.2%)	0.00337 (0–0.019)
Tumour gradeb
G1, G2	140 (96.6%)	0.00305 (0.00013–0.028)	0.1843
G3	5 (3.4%)	0.00090(0.00067–0.009)
Mucinousb
Yes	25 (16.3%)	0.0033 (0–0.018)	0.9469
No	128 (83.7%)	0.00285 (0.00013–0.028)
Lymph node metastasisb
Yes	95 (61.7%)	0.0034 (0.00013–0.022)	0.0626
No	59 (38.3%)	0.00200 (0–0.028)
TNMb
2	65 (38.9%)	0.002 (0–0.028)	0.0266c
3	102 (61.1%)	0.00357 (0.00013–0.022)
MMR status
Deficient	11	0.00380 (0.00068–0.018)	0.5655
Proficient	155	0.00300 (0–0.028)

Abbreviations: CRC=colorectal cancer; MMR=mismatch repair; TNM=tumour, node, metastasis.

^aAge, is represented as median (range).

^bEvaluated using Wilcoxon Rank Sum test.

^cP<0.05.